Planned confirmatory trial
13 evidence topics · 10 sources
Objective
No evidence found.
Location and study date
Screening to begin in the United States by the end of 2026
Study design
Randomized, standard-of-care-controlled design, November 2026
Standard-of-care control considered after the June 2026 Type B meeting, July 2026
Sham surgery-controlled study recommended after the January 2026 Type A meeting, superseded in June 2026
Eligibility criteria
No evidence found.
Treatment
Ifezuntirgene inilparvovec or standard of care, randomized 2:1
Study outcomes
Rationale for using total functional capacity as the primary endpoint
Total Functional Capacity in the phase I/II data at 48 months
Rate of decline by baseline Total Functional Capacity
“The annual rate of decline for 575 patients with baseline TFC scores of 7 to 13 was 0.97 (SE 0.06), was 0.38 (SE 0.08) for 270 patients with baseline TFC scores of 3 to 6, and was 0.06 (SE 0.1) for 101 patients with TFC scores of 0 to 2.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“These rates of functional decline and the covariates that modify them should be considered in estimating statistical power and designing future therapeutic trials involving HD patients with early or moderately severe disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Absence of placebo response on Total Functional Capacity: GENERATION HD1 placebo arm
Functional ability as a regulatory outcome and ceiling effects in early disease
“The assessment of functional ability as a clinical outcome is deemed essential for therapeutic approval by regulatory agencies such as the FDA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, these scales have limiting ceiling effects that make them unattractive for use in earlier stages of HD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Total Functional Capacity at 65 weeks as the main measure of effectiveness in the Nurzigma application
Internal consistency of the UHDRS domains, including functional capacity
“The Unified Huntington's Disease Rating Scale (UHDRS) was developed as a clinical rating scale to assess four domains of clinical performance and capacity in HD: motor function, cognitive function, behavioral abnormalities, and functional capacity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We found there was a high degree of internal consistency within each of the domains of the UHDRS and that there were significant intercorrelations between the domains of the UHDRS, with the exception of the total behavioral score.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Approximately 200 participants planned
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
- Planned design only: the trial is described in company releases and the Form 10-Q as a randomized, standard-of-care-controlled trial of approximately 200 participants randomized 2:1, with TFC at 36 months as the primary endpoint, and screening is planned to begin in the United States by the end of 2026.
- Control without a sham procedure: after a Type A meeting in January 2026 the FDA strongly recommended a prospective, randomized, double-blind, sham surgery-controlled study; in 2026 it later sought alignment on a confirmatory design that included consideration of a randomized standard-of-care control instead of a sham procedure.
- Primary endpoint: the UHDRS TFC appears to have a ceiling effect in early stage Huntington's disease, and it lacks core clinimetric data on test-retest reliability and internal consistency.
- Timing: the FDA stated that the confirmatory study should be well underway, and potentially fully enrolled, at the time of accelerated approval; the company expects the study to be well underway by the time of potential approval.